PolyMedix Announces Positive Phase I Clinical Data With PMX-30063 Novel Antibiotic Drug Candidate

PolyMedix, Inc. , an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has successfully completed its first-in-man Phase I clinical safety study with the novel antibiotic drug candidate PMX-30063.

More: continued here

Filed under: Biology on December 11th, 2008